Through NIAID’s notice of funding opportunity (NOFO) Advancing Development of Diagnostics for Congenital and Adult Acquired Syphilis (R21, Clinical Trial Not Allowed), you can apply for funding to develop new and advance existing diagnostics to combat congenital and adult acquired syphilis infections by leveraging recent advances in basic research on Treponema pallidum.
Scientific Areas of Research Interest
This NOFO highlights NIAID’s interest in advancing and improving congenital and adult acquired syphilis research. We encourage translational diagnostic development research including the collection and use of clinical samples but do not allow clinical trials.
Although studies on congenital syphilis are our highest priority, we also welcome efforts on adult acquired syphilis diagnosis.
NIAID’s areas of research interest for diagnostic product development include:
- Nucleic acid amplification tests
- Antibody or antigen detection tests
- Metabolomics
- Transcriptomics
- Genomics testing platforms
- Innovative detection technologies and platforms
Do not submit applications in the following areas as we will consider the application nonresponsive and return it without review:
- HIV, SIV, or AIDs-focused applications
- Clinical trials
Award Information
Application budgets should not exceed $275,000 in annual direct costs and must reflect the actual needs of the proposed project.
NIAID intends to fund 8 to 12 awards. The scope of the proposed project should determine the project period, although the maximum project period is 2 years.
Applications are due on November 2, 2023, by 5 p.m. local time of the applicant organization.
Contact Information
For inquiries, contact NIAID’s scientific/research contact, Dr. Jonathan Glock, at jglock@niaid.nih.gov or 301-402-0443. Direct any review-related inquiries to NIAID’s peer review contact, Dr. Frank DeSilva, at fdesilva@niaid.nih.gov or 240-669-5023.